ライフサイエンスコーパス: blood count

1 d no increase or decrease in the markers and blood count.

2 clone did not correlate with improvement in blood count.

3 gingival index (GI); 5) CRP; and 6) complete blood count.

4 eye with no evidence of leucocytosis on the blood count.

5 quantified via body weight loss and complete blood count.

6 as outpatients with at least 1 differential blood count.

7 nalyzer and reported as part of the complete blood count.

8 n mimetic eltrombopag (Promacta) can improve blood counts.

9 and proteomics of brushings, and peripheral blood counts.

10 o in patients with normal or increased white blood counts.

11 ence in CD4, CD8, natural killer, and B-cell blood counts.

12 logic response at 6 months, as determined by blood counts.

13 ed hematopoiesis resulting in low peripheral blood counts.

14 h rapamycin significantly normalizes the low blood counts.

15 (77%) were detected by clinical symptoms or blood counts.

16 n underlies variation in baseline peripheral blood counts.

17 r therapeutic approach to improve peripheral blood counts.

18 l consumption all had significant effects on blood counts.

19 in transfusion independence and near-normal blood counts.

20 een dysregulated Janus kinase 2 and elevated blood counts.

21 econstitution was assessed by doing complete blood counts.

22 d with previous chemotherapy than peripheral blood counts.

23 other than a mild, reversible suppression of blood counts.

24 entified in individuals with normal complete blood counts.

25 (EG), leading to dysregulation in neutrophil blood counts.

26 irst year of life, and had normal peripheral blood counts.

27 ion studies, serum chemistries, and complete blood counts.

28 n was determined by assessment of peripheral blood counts.

29 in the blood and marrow, were compared with blood counts.

30 area (m2), and correlated with post-therapy blood counts.

31 d and bone marrow cells, as well as improved blood counts.

32 nal ICUS (CCUS) and MDS as were mean age and blood counts.

33 1) in sputum and a 100% decrease (day 28) in blood counts.

34 8) in sputum and a 100% decrease (day 84) in blood counts.

35 y diagnosed ALL (1 to 9 years old with white blood count 50 000/mm3 or more, or 10 years of age or ol

36 sly clear peripheral blasts (89%), normalize blood counts (74%), and maintain a complete remission (6

37 mAA was defined as depression of 2 of the 3 blood counts: absolute neutrophil count 1200/mm3 or less

38 ve toxicity was lacking, and the recovery of blood counts after AuBMT was rapid.

39 10, respectively) achieved normalization of blood counts after six (57% and 90%, respectively) and 1

40 rom 4-23 days post-treatment, and a complete blood count along with blood chemistry analyses were obt

41 e attributed to intrinsic variation in white blood count among the donors.

42 investigate the prevalence of low peripheral blood counts among HCV-infected adults in the United Sta

43 Parameters of blood count analysis (elevated leukocyte and platelet co

44 Complete blood count analysis demonstrated that disruption of int

45 5.1% of subjects (78 of 1520) with a normal blood count and 13.9% (309 of 2228) with lymphocytosis.

46 who were 62 to 80 years of age with a normal blood count and 2228 subjects with lymphocytosis (>4000

47 Her complete blood count and basic metabolic profile were unremarkabl

48 High fever, viraemia and abnormalities in blood count and blood chemistry were evident in many ani

49 llopurinol prescription, and QI 3 = complete blood count and creatine kinase check every 6 months for

50 Laboratory test results, including complete blood count and electrolyte, creatinine, creatine phosph

51 After adjustment for sex, age, and white blood count and excluding chemotherapy-treated patients

52 Patient underwent full blood count and haemoglobin electrophoresis to exclude t

53 d individuals (aged >45 years, with a normal blood count and no history of cancer) in the UK.

54 oppositely associated with presenting white blood count and PML-RARalpha type: ACA, low, L-isoform;

55 K1/2 inhibitor ruxolitinib lowered the white blood count and reduced spleen weight.

56 Routine biochemistry (full blood count and renal function) results were normal.

57 All DS neonates had multiple blood count and smear abnormalities.

58 risk of ML-DS, we suggest GATA1 mutation and blood count and smear analyses should be performed in DS

59 Newborns frequently exhibit abnormal blood counts and a clonal preleukemia.

60 In vivo blood counts and animal weights were consistent with min

61 Peripheral blood counts and bone marrow histology were used to asse

62 etween groups (P>.05) in temporal changes in blood counts and chemistries were identified.

63 Complete blood counts and comparison of means and the proportion

64 dividuals age 18 or older who had peripheral blood counts and data on HCV infection.

65 7F) expression displayed marked increases in blood counts and developed phenotypes that closely resem

66 is study we assess the accuracy of capillary blood counts and evaluate the potential of a miniaturize

67 Complete blood counts and flow cytometric analyses were performed

68 However, their long-term effects on blood counts and hematopoiesis are poorly understood.

69 d during outpatient care, including complete blood counts and hepatic and renal function tests.

70 Whereas initial high blood counts and high lactate dehydrogenase as an indica

71 rinostat treatment normalized the peripheral blood counts and markedly reduced splenomegaly in Jak2V6

72 on revealed normal complete and differential blood counts and normal serum chemistry, including a nor

73 Peripheral blood counts and platelet transfusions.

74 was well tolerated with complete recovery of blood counts and reversible nonhematologic toxicities at

75 ever, urticaria, and reversible decreases in blood counts and serum complement levels.

76 These were correlated to blood counts and smears in a subset of patients.

77 we prospectively analyzed clinical findings, blood counts and smears, and GATA1 mutation status in 20

78 essment included abdominal ultrasound, whole-blood counts and smears, determinations of plasma immuno

79 with marked improvement in peripheral white blood counts and splenomegaly.

80 ve to stem-cell transplantation and improves blood counts and survival.

81 titis C virus (HCV) RNA levels, and complete blood counts and underwent liver biopsy at the completio

82 pital laboratory for an urinalysis, complete blood count, and a standard blood chemistry panel.

83 eters, including fever, heart rate, complete blood count, and bacteremia; and evaluated the PCR assay

84 time, partial thromboplastin time, complete blood count, and bleeding time were recorded.

85 autopsy, organ histology and immunostaining, blood count, and chemical profile.

86 cell, gamma-globin synthesis ratio, complete blood count, and chemistry were measured.

87 jects had undergone a phlebotomy, a complete blood count, and cognitive and dietary assessments.

88 gression with physical examination, complete blood count, and liver function tests every 3 months and

89 ion values of high MELD, low MAP, high white blood count, and low albumin.

90 medical tests (electrocardiography, complete blood count, and measurement of serum levels of electrol

91 od cell traits hemoglobin, hematocrit, white blood count, and platelet count.

92 cy), and creatinine concentrations, complete blood count, and vitamin supplementation in 550 white an

93 demographics, CVL types and insertion dates, blood counts, and complications were reviewed through we

94 -STAT signaling, normalization of peripheral blood counts, and improved survival in MPN models at dos

95 ulmonary cytokines, lung histology, complete blood counts, and intestinal proliferation were similar

96 ing skin score, liver function tests (LFTs), blood counts, and lung function tests.

97 logic or psychiatric diagnosis, spleen size, blood counts, and peripheral blast count.

98 nia, which occurred regardless of pretherapy blood counts, and persisted an average of 2 months.

99 r erythroid engraftment and normalization of blood counts, and persistence in some without continued

100 evated plasma chromogranin A level, baseline blood counts, and renal function.

101 tions of ISATX247 and cyclosporine, complete blood counts, and serum chemistry profiles were performe

102 g patients evaluable at 12 months had normal blood counts, and seven (78%) of nine patients were tran

103 2499 patients were smokers and had available blood counts, and so were stratified by mean blood eosin

104 Unless earlier blood counts are available, and they often are not, the

105 Peripheral blood counts are not reliable in characterising airway i

106 re assessed every 3-6 months on the basis of blood counts as defined by the European LeukemiaNet crit

107 , HBsAg level, liver function test, complete blood count, aspartate aminotransferase-to-platelet rati

108 teria (86% vs 40% at 5 years; P<.001) and by blood counts at 3 months (reticulocyte count or platelet

109 g variables, no association was seen between blood counts at diagnosis and future complications.

110 y in the myeloid lineage and did not require blood count (BC) or bone marrow (BM) biopsy for MDS conf

111 ng: age over 71 years, a history of abnormal blood counts before M.D. Anderson (MDA) presentation, se

112 evidence of changes in body weight, complete blood count, blood chemistry profile, cardiac contractil

113 tions for infection (urine culture, complete blood count, blood culture, and wound culture) in the 7

114 Further work-up consisted of a complete blood count, bone marrow biopsy, and immunohistochemical

115 e, race, FLT3 subtype, cytogenetic risk, and blood counts but not with respect to sex (51.7% in the m

116 ere we investigate whether full differential blood counts can predict susceptibility to clinical mala

117 Risk Score (IMRS), composed of the complete blood count (CBC) and basic metabolic profile (BMP), pre

118 Several parameters of preoperative complete blood count (CBC) and inflammation-associated blood cell

119 The complete blood count (CBC) provides a high-level assessment of a

120 ocyte-colony-forming unit (CFU-GM), complete blood count (CBC), and donor chimerism at various days a

121 ion, comprehensive blood chemistry, complete blood count (CBC), and urinalysis.

122 Blood analyses included a complete blood count (CBC), sequential multiple analyzer 24 (SMA

123 Complete blood count (CBC), serum chemistries, bile acid profile,

124 nts received anemia education and a complete blood count (CBC).

125 Clinical observations and complete blood counts (CBC) were performed.

126 physician-ordered blood culture and complete blood count [CBC]), and 102 controls (healthy blood dono

127 Complete blood counts (CBCs) were obtained on the day of injectio

128 Body weights, complete blood counts (CBCs), and blood pressure were obtained to

129 tiles, 2-year HbF levels (4.2% and 3.9%) and blood counts changed little from baseline.

130 The use of complete blood counts, chemistry panels, bone scans, chest radiog

131 s of genotyping, HCV antigen tests plus full blood count/clinical chemistry tests.

132 two HCV antigen tests and US$22 for two full blood count/clinical chemistry tests.

133 d a significantly greater effect in reducing blood counts compared to bone marrow counts (P < 0.001).

134 ismatched allogeneic donor doubled the white blood counts compared with recipients of one single unit

135 Declining blood counts correlated with marked expansion and activa

136 artial haematological recovery of peripheral blood counts (CRh) within the first two cycles.

137 achieved a CR with insufficient recovery of blood counts (CRi).

138 Incorporation of blood count data into the model accounted for the discre

139 FN-gamma was present in T cells prior to the blood count decline in 13, and 12 responded to reinstitu

140 Differential blood counts demonstrated up to an 80% drop in lymphocyt

141 utive in all patients studied, regardless of blood count, disease stage, or treatment status.

142 isorders that are characterized by decreased blood counts due to ineffective hematopoiesis.

143 ing of patient need as determined by patient blood counts during the first cycle of chemotherapy.

144 tery catheter insertions; number of complete blood counts, electrolytes, and cultures sent for labora

145 Laboratory studies included normal blood counts, electrolytes, and renal and liver function

146 regardless of the type of uveitis (complete blood count, erythrocyte sedimentation rate, C-reactive

147 ability of survival) recovered nearly normal blood counts, even during continued treatment.

148 lower, incomplete, and transient, with whole blood counts falling to 7% to 38% injected dose by about

149 cells used for hematopoietic rescue restore blood counts faster than allogeneic bone marrow, without

150 ue for use in diagnostic testing of the full blood count (FBC) at the point-of-care (POC), for which

151 Additional assessments included blood counts, fetal haemoglobin concentration, chemistry

152 BM stem and progenitor cells and of complete blood counts following irradiation.

153 arrying the wild-type gene maintained normal blood counts following MMC administration.

154 Complete remission was defined as normal blood count for age and sex.

155 V-based plasmids increased circulating white blood counts for at least 2 months following a single CL

156 cal response was defined as normalisation of blood counts (for patients with essential thrombocythaem

157 The changes in blood counts from lentivirus injection were associated w

158 Significantly, peripheral blood counts from TgPKR mice decrease with age in associ

159 e patients with robust near-normalization of blood counts had drug discontinued at a median of 28.5 m

160 Blood count, hematocrit, hemoglobin concentration and me

161 nt underwent serial measurements of complete blood count, hepatic profile, coagulation profiles, and

162 ot correlate with age, gender, infection, or blood counts; however, 3 correlated with specific cytogn

163 Mean organ volume and blood counts improved continually between 6 months and 1

164 Blood count improvements meeting the International Worki

165 hes have centered on improving the patient's blood counts in a palliative manner.

166 ependence or complete recovery of peripheral blood counts in a proportion of patients.

167 scular complications and 21 887 longitudinal blood counts in a prospective, multicenter cohort of 776

168 Vemurafenib treatment improved blood counts in all patients, with platelets, neutrophil

169 , led to clinically significant increases in blood counts in almost half the patients.

170 care, oxymetholone, by improving peripheral blood counts in Fancd2(-/-) mice significantly faster.

171 rolonged observation showed normalization of blood counts in most JAK2(V617F) mice, suggesting that t

172 somatic ASXL1 mutations contribute to lower blood counts in otherwise asymptomatic individuals.

173 conditional approach included, in addition, blood count information obtained in the first cycle of t

174 Not the high blood count itself, but complications such as leukostasi

175 immunized macaques, as indicated by complete blood counts, leukocyte differentials and hepatic and re

176 Complete blood counts, liver and renal function test results, and

177 A full blood count; liver function test; and measurements of ur

178 cytotoxic agent by assessment of peripheral blood counts, marrow cellularity, progenitor cell conten

179 -specific likelihood values for the complete blood count may determine risk of infection.

180 r of patients with various abnormal complete blood count measurements, and location-specific hospital

181 aptively identified using recurrent complete blood count measurements, which sufficiently constrain t

182 Red marrow dose, baseline blood counts, multiple bone or marrow (or both) metastas

183 In patients who had achieved normal full blood counts (n = 20), the rate of telomere loss had app

184 in patients with available baseline complete blood counts (n=3717).

185 inear correlation between radiation dose and blood count nadir have been insufficient because they ha

186 White blood counts nearly doubled within 12 hours of surgery b

187 to other established blood tests (e.g. White Blood Count, Neutrophils or C - reactive protein) in pre

188 For the complete blood count, no significant differences were observed be

189 ng to their need of supportive care based on blood counts observed in the first cycle of therapy.

190 i [CR with incomplete recovery of peripheral blood counts]) occurred in 30 of 111 (27%) GO recipients

191 The peripheral blood count of CD14(high)/CD16(+) monocytes correlated w

192 efficiency, in vitro stability, or complete blood count of leukocytes labeled with stabilized 99mTc-

193 Complete blood counts of all three of our patients revealed red b

194 r:Star-mPEG/antimiR-145 with serial complete blood counts of leukocytes and serum metabolic panels, g

195 Blood counts of patients with dyskeratosis congenita or

196 pletion, marrow cellularities and peripheral blood counts of the remaining young and elderly dogs wer

197 ent age, weight, pre- and postoperative full blood counts, operating time, estimated blood loss, conv

198 Mutations in DNMT3A had no impact on blood counts or indices.

199 There were no significant changes in blood counts or serum chemistries indicative of radiatio

200 oints were clinically significant changes in blood counts or transfusion independence.

201 mor growth without any change in the weight, blood counts, or chemistries.

202 a, liver and kidney function tests, complete blood counts, or pathology of major organs are observed

203 s (P < .005), and a failure to normalize the blood count (P = .001).

204 en missense variants of LCT and higher white blood count (p = 4 x 10(-13)).

205 ificantly older (P = .0001), had lower white blood counts (P = .0006), and lower percentages of BM bl

206 agnosis, non-type A patients had lower white blood counts (P = .007), and more often trisomies of chr

207 luded people 30 years or older with complete blood counts performed in usual clinical care and no his

208 ividuals in the cohort, 154,179 had complete blood counts performed under acute conditions and 621,05

209 Initial blood count (performed at an outside hospital) showed el

210 Thus, despite restoration of peripheral blood count, phagocytic defects in the AMs of BMT mice p

211 Complete blood counts, plasma interleukin-6 (IL-6) levels, and bo

212 t's or May-Grunwald-Giemsa, determination of blood counts, platelet size and appearance.

213 diation doses versus fractional decreases in blood counts produced correlation coefficients 0.61, 0.3

214 ody and blood versus fractional decreases in blood counts produced correlation coefficients of 0.38,

215 fect hematopoiesis as determined by complete blood count profiles.

216 Brodin et al. show that the heritability of blood counts rapidly decreases with age for the lymphoid

217 ses and 2 complete responses with incomplete blood count recovery (all with AML treated at/below MTD)

218 a complete remission (CR)/CR with incomplete blood count recovery (CRi) or did not progress after 2 c

219 sion (CR), whereas 11 had CR with incomplete blood count recovery (CRi).

220 ssion and complete remission with incomplete blood count recovery rate (CR + CRi) of 46%.

221 The mean time to blood count recovery was 12 mo after the termination of

222 ssion and complete remission with incomplete blood count recovery) was higher for LDAC + volasertib v

223 omplete remission with incomplete peripheral blood count recovery), and 18% died within 30 days.

224 sion [CR] plus CR with incomplete peripheral blood count recovery), disease-free survival (DFS), dura

225 ogenetic risk, secondary disease, incomplete blood count recovery, and abnormal karyotype pre-HCT, MR

226 ission or complete remission with incomplete blood count recovery, and if the 30 day death rate was 2

227 collected on or closest to the first date of blood count recovery, and MRD was determined by 10-color

228 AML) had complete remission with incomplete blood count recovery, and one (FLT3 wild-type AML) had p

229 eved a morphologic remission with incomplete blood count recovery.

230 asily derived from routine full differential blood counts, reflects an individual's capacity to mount

231 consistently, associated with elevations in blood counts relative to mutation-negative myeloprolifer

232 In conclusion, physical examination and blood count remain the methods of choice for staging and

233 influence of HCV infection on the peripheral blood count remains unknown.

234 Complete blood counts, renal and liver function assessments, prev

235 There was substantial variation in the blood count response of the patients who were administer

236 od and marrow of 8 (20%) of the 40 patients; blood counts returned to normal in three (8%) patients.

237 ine transaminase (ALT), creatinine, and full blood count revealed moderate ALT elevation in <2.5% of

238 A basic serum chemistry test and complete blood count revealed no abnormal findings.

239 Analysis of complete blood counts revealed a median hemoglobin level of 10.6

240 Peripheral blood counts revealed a profound reticulocytosis and thr

241 ipients were followed up with daily complete blood count, scheduled chest radiographs, and biopsies.

242 Blood samples were analyzed for complete blood count, serum chemistry profile, level of alanine a

243 mination, routine laboratory tests (complete blood count, serum creatinine level), urine albumin/crea

244 a) the tests to be obtained daily: complete blood count, serum electrolytes, urea nitrogen, creatini

245 age in mutant mice treated with LPS, whereas blood counts showed a marked neutrophilia that was not s

246 His blood count shows signs of mild iron deficiency anemia.

247 th clinical periodontal parameters, complete blood count, smoking status, and age.

248 They are monitored clinically by complete blood counts, specifically with measurements of platelet

249 Combination treatment improved blood counts, spleen weights, and reduced bone marrow fi

250 t cancer patients (as defined by first-cycle blood counts) starting after the first cycle of chemothe

251 platelets (PLTs) and megakaryocytes (MKs) on blood counts, stem/progenitor cells, and Jak-Stat signal

252 had more rapid recovery of peripheral white blood counts, suggesting a possible protective effect of

253 ra-phenylenediamine staining, and a complete blood count system was used to measure the number of ery

254 A fully operational microfluidic blood-counting system for preclinical pharmacokinetic st

255 id neoplasms, as these cells reverse the low blood counts that cause morbidity and death.

256 ission of the AML, in the presence of normal blood counts, the hematopoiesis stably maintained the ho

257 transient and mild suppression of peripheral blood counts, the numbers of individual stem/progenitor

258 ible/negative (< 1%) yield included complete blood counts (therapy-related leukemia), dipstick urinal

259 with 30% of the mice showing elevated white blood counts, they all died of T-cell lymphoma, which wa

260 rent toxicity, and animals maintained normal blood counts throughout.

261 BTNPs showed better restoration of complete blood count to normal level, and significantly longer me

262 The ratio of individual blood counts to bone marrow counts was 10 (IQR, 2.3 to 9

263 Complete blood counts to measure total eosinophils, fractional ex

264 en with SCA with a neurologic exam, complete blood count, transcranial Doppler ultrasound (TCD), meas

265 ory and laboratory tests, including complete blood count, transferrin saturation, and other chemistri

266 Evaluation of bone marrow, blood counts, transfusions, progression, and survival fo

267 e bone scans, chest radiographs, hematologic blood counts, tumor markers (carcinoembryonic antigen, c

268 resent in four of eight patients (peripheral blood count unavailable for one patient).

269 t asymptomatic mutation carriers have normal blood counts until malignancy develops.

270 ted microfluidic system that performs a full blood count using impedance analysis.

271 diagnosis, the median CD3(+)CD4(+) absolute blood count was 480.5 cells/microL (range, 165-632 cells

272 In all four patients, a normal blood count was achieved within four weeks after treatme

273 nd 3 h after preparation, whereas a complete blood count was obtained at 3 h after preparation.

274 White blood count (WBC), C-reactive protein (CRP) and PCT leve

275 increase (fivefold) in the peripheral white blood count (WBC), including a 10-fold rise in the absol

276 d scan (USS), C - reactive protein and White blood counts (WCC) in aiding early diagnosis in children

277 Blood chemistries, complete blood count, weight, liver, and kidney biopsies were exa

278 level, routine chemistry panel, and complete blood count were determined.

279 e comprehensive metabolic panel and complete blood count were normal throughout and after the pregnan

280 evelopment of bacteremia, and mean bacterial blood counts were all significantly higher in the rabbit

281 Complete blood counts were available for four patients, revealing

282 Blood counts were compared to gold-standard automated cl

283 Blood counts were measured three times each week.

284 Serial blood counts were measured, bronchoalveolar lavage (BAL)

285 Tumor size, survival, body weight, and blood counts were monitored for efficacy and toxicity of

286 Liver chemistries and complete blood counts were monitored, and patients were encourage

287 l signs of dyskeratosis congenita, and their blood counts were nearly normal, but all had severely sh

288 Conversely, white blood counts were never elevated following injection of

289 Complete blood counts were normal or near normal in all patients

290 y of underlying malignancy, and the complete blood counts were normal.

291 l transplantation, peripheral blood complete blood counts were performed and examined for polymorphon

292 Complete blood counts were performed every 2 years.

293 Serial blood counts were performed in 20 women with early-stage

294 , or 10 years of age or older with any white blood count) were enrolled.

295 renal function, liver function, and complete blood count, were within normal limits.

296 ood transfusion rate, school attendance, and blood count-were analyzed by intention-to-treat analysis

297 baseline and at study completion; a complete blood count with differential and comprehensive metaboli

298 Complete blood count with differential, serology screen (includin

299 gy analyzer during performance of a complete blood count with differential.

300 ial (CRh) hematologic recovery of peripheral blood counts within the first 2 cycles.